Previous Close | 0.9417 |
Open | 1.0000 |
Bid | 0.6790 x 200 |
Ask | 1.2500 x 200 |
Day's Range | 0.9305 - 1.0000 |
52 Week Range | 0.8400 - 6.4100 |
Volume | |
Avg. Volume | 117,390 |
Market Cap | 10.302M |
Beta (5Y Monthly) | -0.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.0300 |
Earnings Date | May 10, 2024 - May 18, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments. Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210’s registrational program in PTSD by e
Bionomics ( NASDAQ:BNOX ) First Half 2024 Results Key Financial Results Net loss: AU$15.4m (loss narrowed by 5.2% from...
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY. Spyros Papapet